Recipharm Pharmaservices Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Recipharm Pharmaservices Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $2.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Recipharm Pharmaservices Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $2.5M Trade | TransData Nexus

Recipharm Pharmaservices Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $2.5M Total Trade · DGFT Verified

Recipharm Pharmaservices Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.5M across 4 products in 4 therapeutic categories. Based on 64 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Nitrofurantoin ($1.2M), Isoniazid ($847.2K), Theophylline ($317.2K).

Recipharm Pharmaservices Private Limited — Export Portfolio & Destination Treemap

Recipharm Pharmaservices Private Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Recipharm Pharmaservices Private Limited? — Company Overview & Market Position

Recipharm Pharmaservices Private Limited is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on December 30, 2015, the company is registered under the Corporate Identification Number (CIN) U24230KA2015PTC084997. Its registered office is located at Flat No. 502, B Wing, Building No. 48, Tilak Indrayani Housing Society, Tilak Nagar (W), Chembur, Mumbai, Maharashtra, 400089.

The company operates with an authorized capital of ₹6,581,000,000 (approximately $88 million USD) and a paid-up capital of ₹183,156,330 (approximately $2.5 million USD). As of the latest available data, Recipharm Pharmaservices employs approximately 1,077 professionals. The company's website is www.recipharm.com.

What Does Recipharm Pharmaservices Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Nitrofurantoin$1.2M 2Isoniazid

Product Portfolio — Top 4 by Export Value

Recipharm Pharmaservices Private Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Nitrofurantoin	Advanced Antibiotics	$1.2M	26	3.4%	6
2	Isoniazid	Tuberculosis Medications	$847.2K	24	0.0%	10
3	Theophylline	Respiratory	$317.2K	8	2.0%	9
4	Torsemide	Diuretics	$137.8K	6	0.8%	9

Recipharm Pharmaservices Private Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $2.5M. The top category is Advanced Antibiotics (47.1% of portfolio), followed by Tuberculosis Medications (34.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Recipharm Pharmaservices Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Recipharm Pharmaservices Private Limited operates manufacturing facilities in India, with a registered office located in Mumbai, Maharashtra. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.

3Key Leadership

The leadership team of Recipharm Pharmaservices Private Limited includes:

Srinivas Rao Davuluri: Appointed as Managing Director on December 8, 2023.

Ina Quinn: Appointed as Director on January 5, 2023.

Suresh Nagappa Ganachari: Appointed as Whole-Time Director on November 28, 2022.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Recipharm Pharmaservices Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Recipharm Pharmaservices Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's total export value is $2.5 million USD, with 64 shipments across four therapeutic categories. The top five exported products are Nitrofurantoin ($1.2 million USD), Isoniazid ($847,000 USD), Theophylline ($317,000 USD), and Torsemide ($138,000 USD). These products are distributed across various markets, including the United States, European Union, United Kingdom, Australia, and Japan. Specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

2Emerging Markets

Recipharm Pharmaservices Private Limited's export activities also extend to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, such as WHO prequalification, facilitates access to these markets. Specific details regarding market penetration and regulatory approvals in these regions are not publicly disclosed.

3Geographic Strategy

Recipharm Pharmaservices Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Recipharm Pharmaservices Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's export activities include finished pharmaceutical formulations, which may require FDA approvals for the U.S. market.

2WHO & EU GMP

Recipharm Pharmaservices Private Limited's adherence to international quality standards, such as WHO Good Manufacturing Practices (GMP) and EU GMP, is essential for accessing global markets. Specific certifications and statuses related to WHO prequalification and EU GMP are not publicly disclosed.

3CDSCO & Indian Regulatory

Recipharm Pharmaservices Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are essential for its operations. Specific details regarding these regulatory approvals are not publicly disclosed.

Recipharm Pharmaservices Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Recipharm Pharmaservices Private Limited operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share comparisons and head-to-head analyses are not publicly available, the company's focus on finished pharmaceutical formulations positions it among competitors in both regulated and emerging markets.

2Key Differentiators

Recipharm Pharmaservices Private Limited's key differentiators include its specialization in finished pharmaceutical formulations, adherence to international quality standards, and a concentrated portfolio in specific therapeutic areas. These factors contribute to the company's competitive advantage in serving diverse markets.

3Strategic Position

Recipharm Pharmaservices Private Limited's current strategic direction focuses on the production and export of finished pharmaceutical formulations in specific therapeutic categories. The company's future outlook may involve expanding its product portfolio, enhancing manufacturing capabilities, and exploring new market opportunities to strengthen its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Recipharm Pharmaservices Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Recipharm Pharmaservices Private Limited has demonstrated a consistent track record in exporting finished pharmaceutical formulations, with a total export value of $2.5 million USD and 64 shipments across four therapeutic categories. The company's reliability is indicated by its adherence to international quality standards and regulatory compliance, ensuring the consistency and quality of its products.

2Certifications to Verify

Importers should verify the following certifications when considering Recipharm Pharmaservices Private Limited as a supplier:

FDA Approvals: Confirm the company's FDA facility registrations and approved ANDAs for the U.S. market.

WHO GMP Certification: Ensure the company holds WHO Good Manufacturing Practices certification for compliance with international quality standards.

EU GMP Certification: Verify the company's EU Good Manufacturing Practices certification for access to European markets.

Frequently Asked Questions — Recipharm Pharmaservices Private Limited

How many pharmaceutical products does Recipharm Pharmaservices Private Limited export from India?

Recipharm Pharmaservices Private Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Nitrofurantoin ($1.2M), Isoniazid ($847.2K), Theophylline ($317.2K), Torsemide ($137.8K). Total export value is $2.5M.

What is Recipharm Pharmaservices Private Limited's total pharmaceutical export value?

Recipharm Pharmaservices Private Limited's total pharmaceutical export value is $2.5M, based on 64 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Recipharm Pharmaservices Private Limited cover?

Recipharm Pharmaservices Private Limited exports across 4 therapeutic categories. The largest are Advanced Antibiotics (47.1%, 1 products), Tuberculosis Medications (34.4%, 1 products), Respiratory (12.9%, 1 products).

Get Full Recipharm Pharmaservices Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.